Mats Björeman

903 total citations
11 papers, 227 citations indexed

About

Mats Björeman is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mats Björeman has authored 11 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 6 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mats Björeman's work include Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (3 papers). Mats Björeman is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (3 papers). Mats Björeman collaborates with scholars based in Sweden, United Kingdom and Austria. Mats Björeman's co-authors include Magnus Björkholm, Robert Hast, Gunnar Grimfors, Gösta Gahrton, Anders Österborg, Hans Gyllenhammar, Kristina Carlson, Fredrik Celsing, G. Brenning and Bengt Simonsson and has published in prestigious journals such as Blood, European Journal Of Haematology and Scandinavian Journal of Infectious Diseases.

In The Last Decade

Mats Björeman

11 papers receiving 218 citations

Peers

Mats Björeman
Caterina Stefanizzi Italy
Juan Manuel Alonso‐Domínguez Spain
Angela Passi Italy
Witold Prejzner Poland
Elisa Cerqui Italy
Hélène Labussière‐Wallet France
Stefano D’Ardìa Italy
Katarzyna Jamieson United States
Mariella D’Adda Italy
Vincenzo Mettivier Italy
Caterina Stefanizzi Italy
Mats Björeman
Citations per year, relative to Mats Björeman Mats Björeman (= 1×) peers Caterina Stefanizzi

Countries citing papers authored by Mats Björeman

Since Specialization
Citations

This map shows the geographic impact of Mats Björeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Björeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Björeman more than expected).

Fields of papers citing papers by Mats Björeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Björeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Björeman. The network helps show where Mats Björeman may publish in the future.

Co-authorship network of co-authors of Mats Björeman

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Björeman. A scholar is included among the top collaborators of Mats Björeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Björeman. Mats Björeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Höglund, Martin, Fredrik Sandin, Karin Hellström, et al.. (2013). Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 122(7). 1284–1292. 83 indexed citations
2.
Steegmann, J. L., Mauricette Michallet, Enrica Morra, et al.. (2010). A european observational study of dasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: forte study (ca180-211). 95. 339–339. 1 indexed citations
3.
Michallet, Mauricette, Enrica Morra, Juan Luis Steegmann, et al.. (2007). Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.. Blood. 110(11). 1951–1951. 5 indexed citations
4.
Morra, Enrica, Mauricette Michallet, Juan Luis Steegmann, et al.. (2007). Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.. Blood. 110(11). 1959–1959. 3 indexed citations
5.
Öberg, Gunnar, A. Killander, Mats Björeman, et al.. (2002). Long‐term follow‐up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. European Journal Of Haematology. 68(6). 376–381. 16 indexed citations
6.
Simonsson, Bengt, Gunnar Öberg, Mats Björeman, et al.. (1996). Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.. PubMed. 17 Suppl 3. S63–4. 9 indexed citations
7.
Simonsson, Bengt, Gunnar Öberg, A. Killander, et al.. (1994). Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Swedish CML-group.. PubMed. 14 Suppl 3. S55–6. 4 indexed citations
8.
9.
10.
Fredlund, Hans, et al.. (1990). A 10-year Survey of Clinically Significant Blood Culture Isolates and Antibiotic Susceptibilities from Adult Patients with Hematological Diseases at a Major Swedish Hospital. Scandinavian Journal of Infectious Diseases. 22(4). 381–391. 24 indexed citations
11.
Björeman, Mats, et al.. (1988). Case report: Thrombotic thrombocytopenic purpura during pregnancy: Treatment with plasma substitution. 9(1). 89–94. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caterina Stefanizzi Breakdown of academic impact, for papers by Juan Manuel Alonso‐Domínguez Breakdown of academic impact, for papers by Angela Passi Breakdown of academic impact, for papers by Witold Prejzner Breakdown of academic impact, for papers by Elisa Cerqui Breakdown of academic impact, for papers by Hélène Labussière‐Wallet Breakdown of academic impact, for papers by Stefano D’Ardìa Breakdown of academic impact, for papers by Katarzyna Jamieson Breakdown of academic impact, for papers by Mariella D’Adda Breakdown of academic impact, for papers by Vincenzo Mettivier
Rankless by CCL
2026